Cargando…
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
BACKGROUND: This study assessed the ease of use of tobramycin inhalation powder (TIP) administered via T-326 inhaler versus tobramycin inhalation solution (TIS) and colistimethate sodium (COLI), both administered via nebulizers, for the treatment of chronic pulmonary Pseudomonas aeruginosa infection...
Autores principales: | Greenwood, James, Schwarz, Carsten, Sommerwerck, Urte, Nash, Edward F, Tamm, Michael, Cao, Weihua, Mastoridis, Paul, Debonnett, Laurie, Hamed, Kamal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933634/ https://www.ncbi.nlm.nih.gov/pubmed/28614995 http://dx.doi.org/10.1177/1753465817710596 |
Ejemplares similares
-
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013) -
Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017) -
Tobramycin inhalation powder for the treatment of pulmonary
Pseudomonas aeruginosa infection in patients with cystic
fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017) -
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020) -
Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)